作者
Mary Wu, Emma C Wall, Edward J Carr, Ruth Harvey, Hermaleigh Townsley, Harriet V Mears, Lorin Adams, Svend Kjaer, Gavin Kelly, Scott Warchal, Chelsea Sawyer, Caitlin Kavanagh, Christophe J Queval, Yenting Ngai, Emine Hatipoglu, Karen Ambrose, Steve Hindmarsh, Rupert Beale, Steve Gamblin, Michael Howell, George Kassiotis, Vincenzo Libri, Bryan Williams, Sonia Gandhi, Charles Swanton, David LV Bauer
发表日期
2022/2/19
期刊
The Lancet
卷号
399
期号
10326
页码范围
715-717
出版商
Elsevier
简介
Omicron, the SARS-CoV-2 B. 1.1. 529 variant of concern (VOC), was first detected in southern Africa in November, 2021, and its BA. 1 sublineage is now dominant in the UK. Omicron BA. 1 contains 32 coding changes in its spike protein (appendix p 2), and it is unclear to what extent its spread is driven by an intrinsic increase in transmissibility or escape from previous infection-induced and vaccine-induced immunity. In the UK, the BNT162b2 (Pfizer–BioNTech) and AZD1222 (ChAdOx1 nCoV-19, Oxford–AstraZeneca) COVID-19 vaccines were administered as part of a primary twodose course. A subsequent third dose of either BNT162b2 or mRNA1273 (Moderna) vaccine has been administered since September, 2021. To determine the ability of vaccineinduced antibodies to neutralise omicron, and to compare this to our previous measurements of VOC neutralisation by BNT162b2 and AZD1222, 1, 2 we carried out …
学术搜索中的文章
M Wu, EC Wall, EJ Carr, R Harvey, H Townsley… - The Lancet, 2022